Ligand Pharmaceuticals
Overview
Ligand Pharmaceuticals is a biopharmaceutical company that operates as a royalty aggregator, investing in the clinical development and commercialization of high-value medicines while licensing its proprietary technology platforms, Captisol and NITRICIL, to global pharmaceutical partners.
Investments
| Company | Date | Stage | Lead |
|---|---|---|---|
| Palvella Therapeutics | Dec 2024 | Private Placement | Co-investor |
| Castle Creek Biosciences | Feb 2025 | Debt | Lead |
| Primrose Bio | Sep 2026 | Growth Equity | Co-investor |
| Zerion Pharma | Jun 2026 | VC Round | Lead |
| invIOs GmbH | Oct 2024 | Series A | Co-investor |
For institutional investors. Book with your work email.
Key People
Melanie Herman
Executive Director Investor Relations and FP&A
Sector & Stage Mix
Industry, funding stage, and valuation band breakdowns.
FAQ
Where is Ligand Pharmaceuticals based?
Ligand Pharmaceuticals is headquartered in Jupiter, Florida, United States.
When was Ligand Pharmaceuticals founded?
Ligand Pharmaceuticals was founded in 1987.
How many portfolio companies does Ligand Pharmaceuticals have?
Ligand Pharmaceuticals has 6 portfolio companies in Caplight's dataset.
What are some companies in Ligand Pharmaceuticals's portfolio?
Portfolio companies visible on Caplight include Palvella Therapeutics, Castle Creek Biosciences, Primrose Bio, Zerion Pharma, invIOs GmbH.
What was Ligand Pharmaceuticals's most recent investment shown here?
Ligand Pharmaceuticals's most recent investment in this portfolio sample was in Primrose Bio in 2026.
What sectors does Ligand Pharmaceuticals focus on?
Ligand Pharmaceuticals focuses on Healthcare & Life Sciences, Healthcare & Life Sciences, Healthcare & Life Sciences, Healthcare & Life Sciences, Healthcare & Life Sciences, Healthcare & Life Sciences.
What company stages does Ligand Pharmaceuticals focus on?
Stage focus information for Ligand Pharmaceuticals is not publicly available.
What is Ligand Pharmaceuticals's AUM?
Ligand Pharmaceuticals's assets under management are estimated between $500.0M and $1.0B.